alr

Ponalrestat is an aldose reductase inhibitor.

ALR2-IN-1 is a potent and selective ALR2 inhibitor with an IC50 value of 1.42 μM. ALR2-IN-1 possesses both antiglycemic and antioxidant activities and can be used to study the complications of diabetes.

ALR-27 serves as an antagonist of the 5-lipoxygenase (5-LOX) activating protein FLAP and exhibits anti-inflammatory properties. It effectively inhibits 5-LOX product formation (>80%) in pro-inflammatory M1-MDM without significantly inhibiting 5-LOX directly. Additionally, ALR-27 decreases prostaglandin and leukotriene (LT) production in neutrophils and enhances the production of specialized prolytic mediators in certain human macrophage phenotypes [1].

ALR-38, a 5-lipoxygenase (5-LOX) inhibitor (IC50: 1.1 μM), possesses anti-inflammatory activity and effectively reduces ROS levels in neutrophils [1].

ALR-6, an antagonist of the 5-lipoxygenase (5-LOX) activating protein FLAP, possesses anti-inflammatory properties. It significantly inhibits 5-LOX product formation (>80%) in pro-inflammatory M1-MDM without substantially affecting direct inhibition of 5-LOX [1].

ALR2-IN-5 (Compound 10a), an ALR2 inhibitor, demonstrates a potent IC 50 of 99.29 nM and exhibits hypoglycemic effects. This compound is useful in diabetes research.

ALR2-IN-6 (compound 9) is a potent competitive inhibitor of ALR2, with a Ki value of 0.064 μM. It is applicable in research related to neuropathy, retinopathy, and nephropathy.

ALR2-IN-7 (Compound 5a) is a potent and selective inhibitor of alditol reductase (ALR2/AKR1B1) with a Ki of 8.71 nM. It holds potential for research into diabetic complications such as retinopathy and nephropathy, as well as cancer.

ALR2-IN-9 is a potent inhibitor of ALR2 with an IC50 of 21.8 nM, demonstrating excellent antioxidant activity with an EC50 of 2.8 μM in DPPH free radical scavenging. It directly interacts with reactive oxygen (ROS) and reactive nitrogen species (RNS), blocking free radical chain reactions, and acts as an endogenous enzyme antioxidant regulator to modulate catalase (CAT) and superoxide dismutase (SOD) enzyme functions. By influencing the PI3K/Akt/Nrf2 pathway, ALR2-IN-9 inhibits excessive mitochondrial superoxide production induced by hyperglycemia in vitro and ameliorates oxidative stress induced by CuSO4 and H2O2 in vivo models. The compound also extends the lifespan of *Caenorhabditis elegans* by regulating stress response genes such as PMK-1 and shows potential as an anti-aging candidate. ALR2-IN-9 can be utilized in diabetes complication research.

ALR2-IN-8 is a potent inhibitor of aldose reductase (ALR2/AKR1B1) with a KI value of 7.34 nM. It exhibits very low toxicity in normal cells and has a relatively weak direct cytotoxic effect on cancer cells. ALR2-IN-8 is applicable in research related to diabetes and inflammation-associated diseases.

ALR2-IN-10 (Compound 23) is a weak inhibitor of aldose reductase 2 (Aldose Reductase2), showing an inhibition rate of 6% at a concentration of 27 μM. It is applicable in research related to diabetic complications.

ALR1/2-IN-1 (Compound 6e) is an aldehyde reductase (ALR1) inhibitor (IC50: 3.26 μM) and aldose reductase (ALR2) inhibitor (IC50: 3.06 μM) with anticancer effects.

ALR2-IN-2, a potent aldose reductase (ALR2) inhibitor, exhibits IC50 values of 27 nM for rat ALR2 and 228 nM for ALR1, respectively. This compound is utilized in the research of diabetic complications.

ALR2-IN-2, a potent aldose reductase (ALR2) inhibitor, demonstrates IC50 values of 22 nM for rat ALR2 and 116 nM for ALR1, respectively. This compound is utilized in diabetic complications research.

Minalrestat(ARI-509) is an orally active and potent aldose reductase inhibitor for the study of impaired microvascular reactivity in diabetic patients.

Epalrestat (ONO2235), an aldose reductase inhibitor, is well tolerated in Long-term therapy. It can effectually ameliorate the associated symptoms of diabetic neuropathy and delay the progression of the disease, particularly in patients with limited microangiopathy and good glycemic control.

Valrocemide (TV1901), also known as TV-1901, is an antiepileptic drug (AED). Valrocemide has a broad spectrum of anticonvulsant activity and promising potential as a new AED. Valrocemide is an anticonvulsant agent under development by Teva and Acorda as a potential therapeutic for the treatment of epilepsy.

Alrizomadlin is an orally active MDM2 inhibitor. APG-115 shows significant dose-dependent inhibitory effects on TP53wt AML cell lines. The IC50 values ​​are 26.8 nM for MOLM-13 cells and 165.9 nM for MV-4-11 cells. , OCI-AML-3 cells 315.6 nM. Alrizomadlin blocks the interaction of MDM2 and p53 and induces cell cycle arrest and apoptosis in a p53-dependent manner.

Walrycin B is a new-type antibacterial compound targeting the WalR response regulator.

CALR ligand 1 (Compound 2a) is a calreticulin (CALR) ligand with anti-tumor activity against triple-negative breast cancer (TNBC) cells, exhibiting an IC50 of 0.1 μM. It induces intracellular calcium overload, leading to apoptosis in TNBC cells, making it a promising candidate for further research on triple-negative breast cancer.

ALRT 1550, a retinoic acid agent (RAR) agonist, is used potentially for the treatment of cervical carcinoma.

Alrestatin (AY-22284) is a specific inhibitor of aldose reductase and attenuates glucose-induced angiotensin II production in rat vascular smooth muscle in vitro.

Alrestatin is a specific inhibitor of the aldose reductase enzyme.

ALRN-6924 is a novel dual MDM4 and MDM2 inhibitor.